Ironcrose (Iron)

Ironcrose delivers a stable iron‑carbohydrate complex that releases elemental iron after infusion. The iron is captured by reticulo‑endothelial cells, stored as ferritin, and later transferred to transferrin for transport to the bone marrow, where it supports hemoglobin synthesis and red blood cell production.

The dose of Ironcrose is individualized based on the patient’s iron deficit, hemoglobin level, body weight and clinical condition. The prescribing clinician determines the total iron requirement and the infusion schedule, which may be given as a single dose or divided over several sessions.

Safety data for Ironcrose in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Ironcrose, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Ironcrose is a low‑molecular‑weight iron‑carbohydrate complex that releases iron more gradually than some high‑molecular‑weight formulations, resulting in a lower incidence of acute hypersensitivity reactions. Compared with ferric gluconate or iron sucrose, it offers similar efficacy for hemoglobin correction but may differ in dosing frequency and infusion time.

Ironcrose must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. Before administration, allow the product to reach room temperature if required by the specific preparation instructions.

Ironcrose is administered by intravenous infusion, typically through a peripheral or central venous line. The infusion rate and total volume are determined by the prescriber and may be adjusted based on patient tolerance. Monitoring of vital signs during and after the infusion is recommended.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, acute hypotensive shock, and rare events like acute respiratory distress syndrome or hemolysis. Prompt recognition and immediate medical intervention are essential if any signs of a severe reaction occur during or after infusion.

Ironcrose should be avoided in patients with known hypersensitivity to iron‑carbohydrate complexes, those who have experienced previous severe reactions to any intravenous iron product, and individuals with active, uncontrolled infections where iron supplementation could exacerbate the condition.